Exploring how epigenetic changes affect skin cancer development
Official title: Harnessing epigenetic therapy for cutaneous squamous cell carcinoma by targeting histone H3K9 methylation
Funded at Minneapolis VA Medical Center · NIH-10927704 · Data updated 2026-11-12
This study is looking at how a specific gene might affect the development of skin cancer, especially in military personnel who are often exposed to the sun, with the hope of finding new ways to treat this common condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Minneapolis VA Medical Center NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | November 1, 2024 |
| Project end | October 31, 2028 |
| Funding year | 2025 |
| NIH project number | 1I01BX006311-01A1 |
| Project ID | NIH-10927704 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with a history of cutaneous squamous cell carcinoma, particularly those with significant UV exposure.
✕Less likely to help
Patients with other types of skin cancer or those without a history of UV exposure may not benefit from this research.
What this research studies
This research focuses on cutaneous squamous cell carcinoma (SCC), a common skin cancer that particularly affects military personnel due to high UV exposure. The study aims to understand the role of the hairless gene in regulating epigenetic changes that may contribute to SCC development. By investigating how this gene influences histone methylation, the research seeks to uncover new mechanisms behind SCC growth and potentially identify novel therapeutic targets. Patients may benefit from insights that could lead to improved treatment options for SCC.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that more effectively target cutaneous squamous cell carcinoma.
How similar studies have gone: Previous research has shown promise in understanding epigenetic mechanisms in cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Minneapolis VA Medical Center
Minneapolis, United States Active
Researchers
- Principal investigator: Goldfarb, Noah I — Minneapolis VA Medical Center
- Study coordinator: Goldfarb, Noah I
Related research
Other NIH-funded projects on the same topics.
-
Genomic map of cutaneous squamous cell carcinoma and its earliest genetic changes
This project looks at the genes involved in a common skin cancer (cutaneous squamous cell carcinoma) to understand what mutations drive its growth and how it evolves from benign skin lesions.
-
Genetic landscape and evolution of cutaneous squamous cell carcinoma
Researchers will look at DNA changes in skin squamous cell carcinoma and in nearby precursor lesions to find mutations that drive the cancer.
-
Understanding Twist1 to Prevent and Treat Skin Cancer
This work explores how a protein called Twist1 contributes to squamous cell skin cancer and aims to find new ways to stop or treat this disease.
-
Understanding the genetic changes in skin cancer
This study is looking at how certain genetic changes in skin cells can lead to squamous cell carcinoma, a type of skin cancer, by comparing cancerous spots with their non-cancerous beginnings, to help find better ways to catch and treat this cancer early for patients like you.
-
Understanding the genetic changes in skin cancer
This study is looking at how certain genetic changes in skin cells can turn a harmless skin condition into squamous cell carcinoma, a type of skin cancer, to help find better ways to diagnose and treat it.
-
Investigating T cells that target specific cancer proteins in skin cancer
This study is looking at how certain immune cells can help fight a common skin cancer called cutaneous squamous cell carcinoma (cSCC), using a mouse model to learn how to make treatments that boost the immune system even better for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.